This company listing is no longer active
ORIA Stock Overview
Orion Biotech Opportunities Corp. does not have significant operations.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Orion Biotech Opportunities Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.23 |
| 52 Week High | US$12.00 |
| 52 Week Low | US$9.71 |
| Beta | 0 |
| 1 Month Change | -0.29% |
| 3 Month Change | 0.69% |
| 1 Year Change | 4.71% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 6.56% |
Recent News & Updates
Recent updates
Shareholder Returns
| ORIA | US Capital Markets | US Market | |
|---|---|---|---|
| 7D | 0% | -2.7% | -3.7% |
| 1Y | 4.7% | 22.5% | 20.2% |
Return vs Industry: ORIA exceeded the US Capital Markets industry which returned 0.3% over the past year.
Return vs Market: ORIA matched the US Market which returned 4% over the past year.
Price Volatility
| ORIA volatility | |
|---|---|
| ORIA Average Weekly Movement | 8.2% |
| Capital Markets Industry Average Movement | 3.4% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ORIA has not had significant price volatility in the past 3 months.
Volatility Over Time: ORIA's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | n/a | Ruijin , James Huang | orionbiotechopportunities.com |
Orion Biotech Opportunities Corp. does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company intends to acquire businesses in the biotechnology and life sciences sectors.
Orion Biotech Opportunities Corp. Fundamentals Summary
| ORIA fundamental statistics | |
|---|---|
| Market cap | US$255.75m |
| Earnings (TTM) | US$8.76m |
| Revenue (TTM) | n/a |
29.2x
P/E Ratio0.0x
P/S RatioIs ORIA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ORIA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | -US$8.76m |
| Earnings | US$8.76m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.35 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ORIA perform over the long term?
See historical performance and comparison